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Interferon gamma (IFNT) represents an essential cyto- 
kine involved in murine cytomegalovirus (MCMV) 
clearance from the salivary gland and the control of 
horizontal transmission. Because IFN 7 cannot be re- 
sponsible for all cytokine effects during recovery from 
MCMV infection we have now tested the potential 
participation of tumour necrosis factor alpha (TNFct) in 
the antiviral defence. Neutralization of endogenous 
TNF~ abolished the antiviral activity of CD4 T cells in 
immunocompetent as well as in CD8 subset-deficient 
mice. These data suggest hat the antiviral effect of the 
CD4 subset requires the presence of at least two 
cytokines, namely IFN7 and TNF~. Depletion of 
endogenous TNF~ in adoptive cell transfer ecipients 
diminished the antiviral function of CD8 T lymphocytes 
suggesting that TNFct also participates in CD8 T cell 
effector functions. Furthermore, endogenous cytokines 
were found to be required for survival after infection 
with lethal doses of MCMV, whereas immunotherapy 
with recombinant TNF~ and IFN~ could not limit virus 
replication in vivo. The results suggest hat, similar to 
IFNy, TNFct is an integral part of the protective 
mechanisms involved in cytomegalovirus clearance. 
Introduction 
Recovery following a primary infection with cytomegalo- 
virus (CMV) requires the function of T lymphocytes that 
limit the pathological manifestations and eliminate the 
cells supporting virus growth. However, it is commonly 
accepted that T lymphocytes limit virus replication ot 
only by direct cytolytic activity against infected cells 
but also by producing various cytokines at the site of 
infection (for reviews, see Doherty et al., 1992 and 
Ramshaw et aI., 1992). The medical interest in human 
CMV (HCMV) is due to its propensity to cause severe 
diseases in congenitally infected infants and immuno- 
compromised patients (Meyers, 1984; Stagno et al., 
1986). HCMV is the most frequent viral cause of death 
in patients with AIDS (Drew, 1988), in spite of the 
presence of functional virus-specific CD8 T lymphocytes 
(Walker et al., 1987). The inability of T lymphocytes in
AIDS patients to control virus infection has been 
associated with the diminished capability of mono- 
nuclear cells in the production of cytokines, namely 
interleukin (IL)-2 (Kirkpatrick et al., 1985), tumour 
necrosis factor alpha (TNF~) (Ammann et al., 1987) and 
interferon gamma 0FNy) (Murray et aL, 1984). Thus, 
the role of cytokines in recovery from CMV infection 
under normal physiological conditions, as well in various 
pathological conditions, needs to be addressed. 
Our own studies with the mouse model for CMV 
infection concentrated on the characterization of the 
protective principles (for reviews, see Koszinowski et al., 
1990, 1992), definition of major antigens (Reddehase & 
Koszinowski, 1989), identification of antigenic peptides 
presented by the major histocompatibility complex 
(Reddehase t al., 1989), principles of variable antigen 
presentation during viral replication (Del Va let  al., 
1989) and the construction of experimental recombinant 
vaccines (Volkmer et al., 1987; Jonjid et al., 1988; Del 
Valet  al., 1991a, b). It has been shown that CD8 T 
lymphocytes are the major protective principle involved 
in murine CMV (MCMV) clearance (Reddehase t al., 
1985, 1987). In otherwise healthy hosts, CD8 T cells do 
not even require the presence of CD4 helper T lympho- 
cytes for virus elimination (Reddehase et al., 1988). The 
only exception is the salivary glands, where MCMV 
clearance requires cooperation with the CD4 subset 
(Jonjid et al., 1989). However, under specific exper- 
imental circumstances, such as depletion of the CD8 T 
cell subset, CD4 T lymphocytes fully compensate for the 
CD8 deficiency. Mice retaining the CD4 T cell subset can 
therefore clear CMV in all tissues including the salivary 
glands with clearance kinetics imilar to those of normal 
mice (Jonjid et al., 1990). 
Although essential for this compensatory antiviral 
activity, CD4 T lymphocytes are not protective on their 
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own. These findings strongly point to the role of 
cytokines in the control of CMV infection. Experiments 
using in vivo neutralization of IFNy provided evidence 
for the role of this cytokine in T lymphocyte-mediated 
virus clearance (Lu6in et al., 1992). However, its direct 
anti-CMV effect is questionable, since the effect requires 
high concentrations of the cytokine in vitro. In the 
present study we provide evidence that TNF0~ produced 
endogenously during MCMV infection also can play an 
important role in restricting CMV replication. 
Methods 
Mice. Six- to 8-week-old BALB/c mice were obtained from our 
breeding colony at the Faculty of Medicine, University of Rijeka. They 
were bred and housed under barrier conditions and were specific 
pathogen-free. 
Virus, virus titration and infection conditions. Sucrose gradient- 
purified mouse embryo fibroblast culture-propagated MCMV (Smith 
strain, code VR-194, ATCC) was used. The infective virus in tissues 
was quantified by a plaque assay (Reddehase t al., 1985). The 
detection limit was 100 p.f.u, of MCMV per organ homogenate. Virus 
titres (x and y) were regarded as significantly different for P (x versus 
y) < e = 0.05 (one-sided), where P is the observed probability value 
and ~ is a selected significance l vel (Wilcoxon-Mann-Whitney xact 
rank sum test). Mice were infected by injection of 2 x 105 p.f.u, of 
MCMV into a hind footpad. The third passage of salivary gland isolate 
of MCMV was prepared and used in challenge xperiments, according 
to the protocol described elsewhere (Jonjid et al., 1988). 
Reagents and antibodies. Recombinant (r) murine TNF~ and rIFNy 
were generously provided by G. R. Adolf, Bender Vienna, Vienna, 
Austria. The specific activity of rlFN7 stock (lot no. H3. RD48) was 
107 units (U)/mg, as determined by the L cell encephalomyocarditis 
virus bioassay. Specific activity of rTNFc~ stock was 5 x 107 U/rag, as 
determined by cytotoxic assay on L929 cells. 
Monoclonal antibodies (MAbs) and antisera included YTS 191.1.2 
(rat IgG2b) which recognizes the routine CD4 antigen, YTS 169.4.2 
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Fig. 1. Specificity and neutralizing capacity of polyclonal rabbit anti- 
TNFc~ serum. The ability of the rabbit antiserum to neutralize 50 U/ml 
of murine natural (D) or recombinant (•) and human recombinant 
(C)) TNF was tested in an L929 cell bioassay. Results represent the 
mean value of triplicate cultures. 
(rat IgG2b) which is specific for mnrine CD8 antigen (Cobbold et al, 
1984), R4.6A2 (rat lgG1) which neutralizes murine IFN? (Spitalny & 
Havell, 1984), and l lB l l  (rat IgG1) which neutralizes murine IL-4 
(Ohara & Paul, 1985). MAbs were partially purified from ascitic fluid 
by ammonium sulphate precipitation followed by dialysis in PBS 
(pH 7.6) and stored at -30  °C. 
Natural mouse TNF was produced according to the procedure 
described by Silva & Faccioli (1992). In brief, peritoneal cells (5 x 10 ~) 
were stimulated with Iipopotysaccharide (10~tg/mt) overnight and 
supernatant was tested in the L929 cell bioassay. 
The anti-TNFc~ antibody used was polyclonal rabbit antiserum 
raised against pure rTNFe and was capable of neutralizing both 
natural and recombinant TNFc~ (Fig. 1). The antiserum was produced 
according to the protocol described by Nauciel & Espinasse-Maes 
(1992). Rabbits were immunized by subcutaneous injections of 10 pg of 
TNFc~ in complete Freund's adjuvant. Two weeks later animals were 
boostered with the same amount of TNFa in incomplete Freund's 
adjuvant and again, with 5 gg rTNF~ in saline, 3 days before bleeding. 
The antiserum was extensively dialysed against PBS and stored at 
-30  °C before use. 
L929 TNFbioassay. The assay was carried out as described elsewhere 
(Wang et al., 1985). Neutralization of rTNFc~ with various anti-TNFc~ 
serum dilutions was performed at 4 °C over 1 h. After the neutral- 
ization, 100 ~tl of each sample was added to L929 cells. The test was 
done in the presence of 4 gg/ml actinomycin D. After overnight 
incubation at 37 °C with 5 % CO 2 in air, TNF-mediated cytopathic 
effects on L929 cells were visualized by crystal violet staining. The 
neutralizing capacity of anti-TNF~ serum was defined as the reciprocal 
value of the highest serum dilution that, when reacted with an equal 
volume of test sample containing 1ng/ml rTNFc~, neutralized 50 % or 
more of the cytotoxic activity. According to this assay 1 rrd of anti- 
TNFa serum was able to neutralize approx. 6.4 gg of rTNFa 
(3.2 x 105 U). 
In vivo treatment of  mice. In vivo depletion of CD4 + and CD8 + T 
lymphocyte subsets was carried out as described previously (Jonjid 
et al., 1989, 1990). Immunocompetent mice, either euthymic or thy- 
mectomized as well as adoptive transfer recipients, were injected 
intraperitoneally with 1 mg of anti-CD4 and anti-CD8 MAb every 
fourth day, starting 1 h after infection and cell transfer. For in vivo 
neutralization of IFNy and IL-4, mice were injected with 200 l.tg of 
R4.6A2 and 11B11 MAbs, respectively, every other day starting 1 h 
after infection. If not stated otherwise, the neutralization ofendogenous 
TNFc~ was accomplished by intravenous injection of 100 gl of rabbit 
anti-TNF serum and this treatment was repeated every other day for 2 
weeks. A control group of mice received the same amount of normal 
rabbit serum. 
The prophylactic adoptive cell transfer was performed as described 
previously (Reddehase t al., 1985). In brief, recipient mice were 
immunodepleted by total-body 7-irradiation, with 6 Gy delivered as a 
single dose. Spleen cells from donor mice were infused into the tail vein 
2 h after irradiation and infection. Virus titres in tissues of recipients 
were determined 2 weeks later. 
Results 
Failure of immunotherapy with exogenous TNFc~ alone 
or combined with IFN?, to limit MCMV replication in 
vivo 
It has been shown that rIFN~ on its own has only a 
moderate direct antiviral effect in vitro and when given in 
vivo fails to prevent MCMV replication in immuno- 
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Table 1. Therapy with rTNFct either alone or in 
combination with rIFN 7 cannot replace antiviral 
function of T cells in vivo 
Protocol* Treatment 
Range ofvirus 
titres in 
salivary glands 
(log10 p.f.u.)t 
(a) Control~: 6"1-6"8 
rTNFct 6"~6"7 
rlFN 7 6.1-6-3 
rTNFct + rIFN 7 6.4~6.9 
(b) Control 6.0-6.5 
rTNFct 6.0-6.8 
rIFN 7 6.1 6.5 
rTNFct + rIFN 7 6.2-6.4 
(c) Control 5.5-6.0 
rTNFct 5.3 6.1 
rIFN7 5.2-5.6 
rTNFa + rlFN 7 ND§ 
(d) Control 5.6-5.9 
rTNF~ 5.26.9 
rIFN7 5.5-6.1 
rTNF~ + rIFN 7 ND 
* (a) Irradiated (6 Gy) and MCMV-infected BALB/c mice were 
injected either with 400 ng of rTNFe, 2 gg of rIFN 7 or a combination 
of both cytokines, every other day for 2 weeks. (b) Irradiated (6 Gy) 
and MCMV-infected mice were transferred with2.5 x 10 ~ non-primed 
spleen cells and treated with recombinant cytokines as above. (e) 
Irradiated (6 Gy) and MCMV-infected mice were transferred with 
2.5 x 10 ~ MCMV-primed spleen cells and treated with recombinant 
cytokines as above. (d) Thymectomized mice were depleted of CD4 T 
lymphocytes and infected with MCMV. Treatment with cytokines was 
initiated after 2 weeks as above. 
I" Six mice were used per group. The data represent the range of 
titres found in individual mice. 
:~ The control groups of mice were injected with PBS alone. 
§ YD, Not determined. 
deficient mice (Lu~in et al., 1992). To investigate the 
effect of TNF~ and its possible synergy with IFN  7 in 
vivo, mice were immunodepleted by 6 Gy total-body 7- 
irradiation and infected with MCMV. Following this 
treatment animals were transferred either with normal 
syngeneic lymphocytes or with immune spleen cells 
derived from mice latently infected with MCMV, or were 
left untransferred. Each group was divided into sub- 
groups that were treated with recombinant cytokines as 
indicated in Table 1. Treatment with cytokines was 
repeated every other day for 2 weeks when the mice were 
sacrificed and virus titres in tissues were determined. 
Neither rTNFct alone, nor in combination with rIFNT, 
had a significant effect on virus spread in vivo, whether 
given to nontransferred immunodepleted mice (Table 
1 a) or to mice transferred with nonprimed lymphocytes 
(Table 1 b). In accordance with our previous findings for 
rIFNT, rTNF~ also failed to enhance antiviral capacity 
of MCMV-primed spleen cells transferred to immuno- 
depleted recipients (Table 1 c). Taken together, immuno- 
therapy with rTNF~ and rIFN7 could not limit virus 
replication in vivo and could not enhance the antiviral 
effect of transferred lymphocytes. Compatible results 
were obtained in three independent experiments, one of 
which is shown. 
In addition, we tested whether TNFct can limit virus 
replication in salivary glands of CD4 subset-depleted 
mice persistently infected with MCMV. Two weeks after 
MCMV infection and CD4 subset depletion, when 
persistent MCMV infection in salivary glands was 
established, mice were treated with rTNFc~ or with 
r IFN7 for 2 weeks, after which virus titres in salivary 
glands were determined. As shown in Table l(d), 
treatment with rTNFct had no effect on virus titres in 
salivary glands. Therapy, with r IFN7 was also ineffective, 
in agreement with previously published data (Lu6in et 
al., 1992). 
Evidence for the role of endogenous TNF~ #z limiting 
MCMV replication in vivo 
Attempts to treat viral infections by the administration 
of recombinant cytokines have been largely unsuccessful 
(Klavinskis et al., 1989; Soike et al., 1989), probably 
because of the short half-life of recombinant cytokines in 
vivo and the need for their localization at the sites of viral 
infection. Therefore, the inability of rTNF~ to mount 
anti-MCMV activity and to synergize with r IFN 7 in vivo 
does not rule out the possible physiological functions of 
this cytokine. To determine whether TNF~ is involved in 
the response to MCMV, endogenous TNF~ was neutral- 
ized in vivo. Groups of normal immunocompetent 
BALB/c mice were injected either with rabbit antiserum 
against mouse TNF~ or, as a control, with normal rabbit 
serum (NRS). Antibody treatment was repeated every 
other day for 2 weeks. The effect of TNF~ neutralization 
was compared with the effect of depletion of the CD4 or 
the CD8 T cell subset. Two weeks after infection the 
virus titres in organs were determined. The results shown 
in Fig. 2 reveal that the neutralization of endogenous 
TNF~ in immunocompetent mice resulted in higher virus 
yield from salivary glands in comparison with controls 
and the group of mice that were depleted of CD8 T 
lymphocytes. As expected from previous work (Jonji6 et 
al., 1989), depletion of the CD4 subset resulted in high 
virus titres in salivary glands. Remarkably, and similar 
to previously published data for IFN7 depletion (Lu~in 
et al., 1992), neutralization of endogenous TNF~ in 
otherwise immunocompetent animals did not have a 
significant effect upon virus clearance in tissues other 
than the salivary glands (data not shown). 
The failure of TNF~ neutralization to compromise 
virus clearance in other tissues could be due to the 
amounts of antibody being insufficient o neutralize all 
endogenous TNF~. To investigate this possibility a 
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Fig. 2. Effect of TNFa neutralization the course of MCMV infection 
in the salivary gland. BALB/c mice were compared with respect o 
virus production in the salivary glands 2 weeks post-infection and 
treatment with antibodies to TNFe (immune rabbit serum), CD4 or 
CD8 according to schedule described in Methods. Control group 
received NRS. Titres of individual mice (0) and median values (--) are 
shown. There is a significant difference i  virus titres of anti-TNF~ 
serum-treated and CD4-depleted mice in comparison with control 
group (P < 0.008 and P < 0.001, respectively). 
group of  mice was given anti-TNF0~ serum and clearance 
kinetics of  the ant ibodies were determined. MCMV-  
infected mice were injected with 100 gl of rabbit  anti- 
TNF~ serum, or NRS in controls, and were bled 0, 1, 2 
and 3 days after injection. The neutral iz ing titres of  
ant ibodies persisting in mouse sera were determined 
using the L929 TNF  bioassay. As expected, the excess of  
TNF~ neutral iz ing titres in the sera of  the injected mice 
declined with time after injection but levels were still 
significant 3 days after treatment (Fig. 3). This result 
confirmed that n t i -TNF~ serum used in the experiments 
was appropr iate  for pro longed neutral izat ion of  TNF0~ 
in vivo. Note that in all our experiments the in vivo 
administrat ion of  100gl  of  ant i -TNFe  serum was 
per formed every other day during the course of  the 
experiment. Ant i -TNF7 activity was absent f rom the 
sera of  mice treated with NRS.  It  therefore appeared 
unlikely that the failure of  ant i -TNF~ treatment to affect 
virus repl ication in tissues other than the sal ivary glands 
150 
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Fig. 3. Kinetics of TNFc~ neutralizing antibody titre after transfer. 
MCMV-primed mice received a single dose (100 lal) of rabbit anti- 
TNFc~ serum or NRS. Mice were bled at 2 h, and 1, 2 and 3 days after 
injection, and their pooled sera were tested for TNFe neutralizing 
capacity. The neutralizing capacity of sera was defined as the reciprocal 
value of the highest serum dilution that, when reacted with an equal 
volume of test sample containing 1ng/ml TNF~, neutralized 50 % of 
the cytotoxic activity in the L929 cell bioassay. Results represent th  
mean value of four replicate cultures and the bars represent the S.E.M. 
was due to the administrat ion of  insufficient amounts of  
neutral iz ing antibodies. 
TNF~ is an integral part of CD4 T lymphocyte function 
The fact that TNF~ neutral izat ion abolishes or delays 
MCMV clearance only in the salivary glands of  the 
immunocompetent  host suggests that TNF~ may be 
pr imar i ly  involved in CD4 subset-dependent antiviral  
functions, which only in this organ cannot  be compen- 
sated by CD8 T lymphocytes.  According to the distinct 
cytokine pattern that they secrete, CD4 T cells can be 
functional ly subdivided into T helper type 1 (TH1) and 
TH2 subsets (Mosmann & Moore,  1991). We have 
shown previously that the antiviral  effectors belong to 
the TH1 subset because neutral izat ion of  endogenous 
IFN7 prevents CD4-dependent  antiviral function in 
salivary glands (Lu~in et al., 1992). Therefore, the effect 
of  TNF~ neutral izat ion on virus clearance in animals 
that rely entirely on CD4 subset could affect the virus 
clearance in tissues other than the salivary glands. To test 
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Fig. 4. Effect of TNF~ neutralization  the course of MCMV infection 
in CD8 subset-depleted mice. CD8-depleted mice were treated with 
antibodies to TNFc~ (immune rabbit serum), IL-4 or CD4. The control 
group received NRS. Two weeks after MCMV infection mice were 
compared with respect to virus production i salivary glands, lungs and 
spleen. Virus titres in individual mice (0)  and median values ( ) are 
shown. DL, Detection limit. There is a significant difference in virus 
titres between mice treated with anti-TFN~ serum and the control 
serum for lungs (P < 0.008) and salivary glands (P < 0.005). 
this, CD8-depleted mice were used as a model for the 
assessment of CD4 T cell functions. The mice were 
MCMV-infected and treated with neutralizing antibodies 
to TNF7 and IL-4. As expected from the lack of function 
of CD8 lymphocytes in salivary glands, CD8 subset 
depletion did not potentiate the effect of TNFe  neutral- 
ization in this organ (Fig. 4). The situation was different, 
however, when virus titres were studied in the lungs. In 
contrast to the effect of TNF~ neutralization i  immuno- 
competent mice, lungs of CD8-depleted mice treated 
with anti-TNFe contained significantly more virus. This 
indicates that, in the absence of CD8 T lymphocytes, 
TNFc~ is an essential cytokine for virus clearance in the 
lungs, whereas virus control in the spleen was affected 
only after depletion of the CD4 subset. These results 
suggest that TNF~ plays an important role in CD4 
subset-dependent a iviral function. In contrast with the 
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Fig. 5. Participation of endogenous TNFct in the antiviral activity of 
adoptively transferred lymphocytes. Splenocytes (2x 105) obtained 
from immunocompetent MCMV-primed donors were transferred into 
?,-irradiated (6 Gy) and MCMV-infected syngeneic recipient mice. 
Recipient mice were divided into four subgroups receiving either NRS, 
rabbit anti-TNF~ serum, MAb to IFNT, IL-4 and CD8. Virus titres in 
individual recipient organs measured 2 weeks after adoptive transfer 
and infection (O) and median values (~) are shown. CL, (control level) 
represents the effect of cells obtained from non-primed control d nors; 
DL, detection limit. There are significant differences between virus 
titres of mice treated with anti-TNFct serum and control serum in lungs 
(P < 0-01) and salivary glands (P < 0.008). Virus titres in lungs of anti- 
CDS-treated mice differed significantly (P < fl00 D from virus litres in 
the control group. 
effect of anti-TNF~ serum, neutralization of IL-4 did not 
show any influence on MCMV replication, confirming 
the predominant role of the TH1 subset in MCMV 
clearance. 
Requirement of TNFc~ for antiviral activity of MCMV- 
primed splenoeytes 
In addition, the involvement of endogenous TNF~ in the 
antiviral function of MCMV-primed splenocytes was 
also tested in an adoptive cell transfer system (Fig. 5). 
Cell donors were fully immunocompetent mice, either 
MCMV-primed or non-primed. Irradiated and MCMV- 
infected cell transfer ecipients received, on the day of 
cell transfer, either control serum or antibodies to TNF0~, 
to IFN~, to IL-4 or to CD8. With the exception of anti- 
CD8 MAb that was injected every 4 days, other 
antibodies were injected every other day for 2 weeks until 
the mice were killed and virus titres in tissues were 
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Table 2. Effect of TNFc~ and IFN 7 neutralization on 
survival of mice after infection with salivary gland 
isolate of  MCMV 
Treatment* Survivors/ 
total number 
Auti-IFNy Anti-TNF~ of mice 
- - 10/20 (50 %) 
+ - 1/8 (12%) 
- + 2/8 (25 %) 
+ + 0/8 (0%) 
* Neutralization f endogenous TNF~ and IFN 7 was accomplished 
by in vivo administration f MAb R4.6A2 and rabbit anti-TNFc~ 
polyclonal serum, respectively, at the day of infection with 1 LDs0 
(1 x 105) of salivary gland isolate of MCMV. Antibody treatment was
repeated 48 h after infection. The percentage of survivors i shown in 
parenthesis. 
determined. As expected, depletion of IFN 7 compro- 
mised the virus clearance from the salivary glands. A 
similar effect was seen after neutralization of TNF~ but 
not after neutralization of IL-4 or depletion of the CD8 
subset. The situation was different, however, when the 
lung virus titres were compared. As expected from 
previous studies (Lu6in et al., 1992), neutralization of 
endogenous IFN 7 did affect but did not abolish the 
protective ffect of transferred cells. Essentially the same 
effect was seen in the group of mice treated with anti- 
TNF~ serum. However, depletion of CD8 T lymphocytes 
abolished the protection, yielding high virus titres in 
lungs. Since virus clearance from the lungs is predom- 
inantly the function of CD8 T lymphocytes this ex- 
periment confirmed that TNFe,  as well as IFNT, is less 
important for the control of MCMV infection in the 
lungs than CD8 subset depletion, but that TNF~ 
represents an integral part of CD8 subset-mediated 
effector function. Remarkably, TNF0~ neutralization had 
no detectable ffect in the spleen (data not shown) but 
this is not too surprising because the spleen is the organ 
that controls MCMV infection most thoroughly (Redde- 
hase et al., 1985). Thus, effector mechanisms in the spleen 
are obviously not affected upon neutralization of only a 
single cytokine. 
Cytokine requirement for survival after infection 
with a lethal dose of MCMV 
The effect of the neutralization ofendogenous TNF0~ and 
IFNy on the survival of mice infected with a high dose of 
MCMV was tested. Normal BALB/c mice were infected 
with 1 x 105 p.f.u. (1 LDs0 ) of a salivary gland isolate of 
M CMV (Jonjid et al., 1988) and treated with neutralizing 
antibodies to TNFc~, to IFNT, or a combination of both. 
The results presented in Table 2 show that both cytokines 
are not only marginally involved in virus clearance but 
are essential for resistance to a lethal dose of MCMV. 
Depletion of a single cytokine reduced the number of 
survivors after lethal infection, whereas neutralization of
both resulted in a fatal outcome. 
Discuss ion  
Although it is generally accepted that the resistance to 
many viral infections relies on the activation of T cells, 
the final effector mechanisms by which infected cells are 
eliminated and virus replication is inhibited are not 
understood in detail. Both CD4 and CD8 T cells respond 
to primary MCMV infection in immunocompetent mice, 
but the antiviral protective activity can usually be 
transferred only by CD8 T lymphocytes (Reddehase et 
al., 1985, 1987, 1988). However, the CD4 subset can 
compensate for a complete lack of CD8 T lymphocytes. 
CDS-depleted mice recover from acute MCMV infection 
and the virus establishes latency (Jonjid et al., 1990). This 
points to a hierarchical role of effector functions and 
demonstrates at the same time the flexibility of the 
immune system. 
Since CD4 T cells are not protective by themselves, 
even if derived from the CDS-depleted host, it is 
reasonable to postulate that CD4-dependent effector 
functions are, at least in part, cytokine-mediated. Several 
cytokines how antiviral effects in general, but there is no 
doubt that a central role is played by IFNT, a factor that 
has been implicated in virtually every viral infection 
(Quinnan & Manischewitz, 1987; Leist et al., 1989; 
Karupiah et al., 1990; Kohonen-Corish et al., 1990). We 
have recently demonstrated that IFN~, is a key factor for 
MCMV clearance from salivary glands and, therefore, 
for the prevention of horizontal spread ofCMV (Lu6in et 
al., 1992). However, our studies also indicated that IFN~: 
is not the only cytokine involved in virus clearance from 
salivary glands. The search for such a cytokine focused 
on TNF~, which has been implicated in a number of 
parasitic (Havell, 1987; Titus et al., 1989; Chen et al., 
1992; Johnson, 1992; Silva & Faccioli, 1992), viral 
(Rossol-Voth et aI., 1991; Sambhi et al., 1991) and 
bacterial infections (Nauciel & Espinase-Maes, 1992). 
TNF~ is a pluripotent cytokine with a variety of 
biological properties and is produced by many cell types, 
but mostly by activated macrophages (Larrick & Wright, 
1990). 
The present report provides evidence suggesting that 
TNF~ contributes to the recovery of mice from primary 
infection with MCMV and also has a role in antiviral 
clearance mediated by primed T lymphocytes. Similar 
to the effect of the CD4 subset depletion or of IFNy 
neutralization, the neutralization of TNF0~ abolished or 
delayed virus clearance from salivary glands. Further, in 
CDS-depleted mice TNF~ appeared to be critical for 
virus clearance not only in salivary glands but also in 
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other organs, such as lungs, indicating that TNF~ 
contributes mainly to the CD4 subset-dependent a i- 
viral effector mechanism. The negative ffect of IL-4 
neutralization suggests that this mechanism is dependent 
on the TH1 subset. 
Our results do not exclude a role of TNFa in the CD8 
subset-mediated control of MCMV infection since anti- 
TNF~ treatment affected the protective capacity of 
adoptively transferred cells, which is predominantly 
mediated by CD8 T lymphocytes. Nevertheless, it
appears that the effect of anti-TNFe treatment has a less 
dramatic onsequence onfunctions that rely on the CD8 
subset. The present results have also shown that 
depletion of TNF~ even alters the survival rate of mice 
infected with l LDa0 of MCMV. Since this early host 
defence against a high virus dose requires the active 
participation of natural killer cells and macrophages 
(Bukowski et al., 1985), both TNF~ and IFN 7 probably 
play an important role in the T cell-independent arm of 
the antiviral response. However, it should be noted that, 
owing to the technical conditions of repeated antibody 
injection, ashort half-life of antibody and the uncertainty 
considering the distribution of the antibodies in the 
tissues, our data probably underestimate the role of local 
TNF~ in anti-CMV defence. 
The neutralization f endogenous TNFe indicated its 
important physiological role in the enhancement of host 
resistance to herpesviruses. The nature of the mech- 
anisms involved is not clear. TNFa may enhance host 
resistance against various intracellular parasites and 
viruses by modulating a cascade of specific and non- 
specific defence mechanisms. Such mechanisms include 
the local recruitment of inflammatory cells, triggering 
microbicidal ction by activating macrophages to release 
reactive oxygen metabolites, regulation of production of 
other cytokines and the expression of their receptors, 
promotion of proliferation and differentiation of B 
lymphocytes, and augmentation f humoral immunity 
(for review, see Titus et al., 1991). 
Endogenously produced TNFe has been shown to be 
an important mediator in infection by vaccinia virus. 
TNF~ expressed by recombinant virus demonstrated 
that localized production of this cytokine during viral 
infection leads to the rapid and efficient clearance of 
vaccinia virus in normal and in immunodeficient mice 
suggesting that, once provided in sufficient concen- 
tration, TNF~ can act antivirally in a T cell-independent 
manner (Sambhi et al., 1991). In certain tumour systems, 
however, the protective activity of TNFa has been found 
to rely on T cell-dependent mechanisms (Asher et al., 
1991). This is illustrated by the finding that the ability of 
tumour cells to regress in vivo after transfection with the 
TNFa gene can be prevented by depletion of the CD4 or 
the CD8 subset. Another possibility is that anti-TNF0~ 
serum exhibits its effect by acting directly on CD4 cells 
that display TNFoc on their surface. It has been shown 
that membrane-associated TNF~ is involved in the 
activation of anti-leishmanial defence (Sypek & Wyler, 
1991), and that it may be a mechanism of targeting 
activation signals to macrophages in an antigen-specific 
and genetically restricted manner. Given the fact that 
TNF0~ is synthesized by many cell types and is involved 
in so many defence strategies, the question arises 
whether, for the given infection, major and typical 
producers of the cytokine can be identified. This is 
entirely open for CMV and further studies must show 
whether the inhomogeneous organ distribution of cells 
related to the monocyte and macrophage lineage could 
offer an explanation for the variable organ manifes- 
tations of HCMV disease. 
In the present study we could not demonstrate 
protective ffects of rTNFc~ alone nor synergistic effects 
in combination with rlFN 7. This is not entirely un- 
expected. Although different recombinant cytokines are 
active in vitro, studies in vivo have been hampered either 
because of short half-life or difficulties encountered in 
targeting the molecules to the site of infection or immune 
reaction (Kohonen-Corish et al., 1990; Sambhi et al., 
1991 ; Ramshaw et al., 1992). Our studies confirmed that 
exogenous TNF0c has a very short half-life in vivo: as 
early as 2 h after intravenous injection of 400 ng of 
rTNF~ no residual activity in the serum of treated mice 
could be demonstrated by the cytotoxic assay on L929 
cells (B. Polid, unpublished data). 
In conclusion, our studies in a model system for CMV 
disease are the first to demonstrate hat endogenous 
TNF~ is required in vivo for the efficacious control of 
CMV infection. Neutralization of endogenously pro- 
duced TNF0~ affects the protective capacity of MCMV- 
primed adoptively transferred lymphocytes and prevents 
the clearance of virus from salivary glands of acutely 
infected immunocompetent mice. In addition, during 
CD4 subset control of virus clearance anti-TNFc~ 
treatment compromises virus clearance not only in 
salivary glands but also in the lungs. To assess the 
potential role of cytokines during the different clinical 
manifestations of human CMV disease further studies 
are required to define the conditions under which the 
CD4 subset control gains importance. 
We thank J. Dirlid for excellent echnical assistance, This study 
was supported by the Deutsche Forschungsgemeinschaft (grant 
Ko 571/11) and the Ministry of Science of Croatia. 
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